Diana Andreea Mitrea

Dr. Diana Andreea Mitrea

Bucharest Oncological Institute "Alexandru Trestioreanu", Bucharest, Bucureşti, Romania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in Medicina
Verified
Journal Article
Open access
PDF file
LGLaurentia Nicoleta Gales
Laurentia Nicoleta Gales
LFLeyla Forsea
Leyla Forsea
DMDiana Andreea Mitrea
Diana Andreea Mitrea
SCStefanica Irina Catalina
Stefanica Irina Catalina
ISIrina Carmen Stanculescu
Irina Carmen Stanculescu
LSLuiza Serbanescu
Luiza Serbanescu
Over the last years, repurposed agents have provided growing evidence of fast implementation in oncology treatment such as certain antimalarial, anthelmintic, antibiotics, anti-inflammatory, antihypertensive, antihyperlipidemic, antidiabetic agents. In this study, the four agents of choice were present in our patients’ daily treatment for nonmalignant-associated pathology and have known, light toxicity profiles. It is quite common for a given patient’s daily administration schedule to include two or three of these drugs for the duration of their treatment. We chose to review the latest literature concerning metformin, employed as a first-line treatment for type 2 diabetes; mebendazole, as an anthelmintic; atorvastatin, as a cholesterol-lowering drug; propranolol, used in cardiovascular diseases as a nonspecific inhibitor of beta-1 and beta-2 adrenergic receptors. At the same time, certain key action mechanisms make them feasible antitumor agents such as for mitochondrial ETC inhibition, activation of the enzyme adenosine monophosphate-activated protein kinase, amelioration of endogenous hyperinsulinemia, inhibition of selective tyrosine kinases (i.e., VEGFR2, TNIK, and BRAF), and mevalonate pathway inhibition. Despite the abundance of results from in vitro and in vivo studies, the only solid data from randomized clinical trials confirm metformin-related oncological benefits for only a small subset of nondiabetic patients with HER2-positive breast cancer and early-stage colorectal cancer. At the same time, clinical studies confirm metformin-related detrimental/lack of an effect for lung, breast, prostate cancer, and glioblastoma. For atorvastatin we see a clinical oncological benefit in patients and head and neck cancer, with a trend towards radioprotection of critical structures, thus supporting the role of atorvastatin as a promising agent for concomitant association with radiotherapy. Propranolol-related increased outcomes were seen in clinical studies in patients with melanoma, breast cancer, and sarcoma.

11 May 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
DMDiana Andreea Mitrea
Diana Andreea Mitrea
EFEliza M. Froicu
Eliza M. Froicu
HPHans Prenen
Hans Prenen
MGMaria A. Gambacorta
Maria A. Gambacorta
PSPaul N. Span
Paul N. Span
PPPhilip Poortmans
Philip Poortmans

4 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
LGLaurentia Nicoleta Gales
Laurentia Nicoleta Gales
DMDiana Andreea Mitrea
Diana Andreea Mitrea
BCBogdan Mihai Chivu
Bogdan Mihai Chivu
ARAdrian Radu
Adrian Radu
SBSilvia Bocai
Silvia Bocai
LSLuiza Serbanescu
Luiza Serbanescu
Metastatic lesions of the spine occur in up to 40% of cancer patients and are a frequent source of pain and neurologic deficit due to cord compression. Palliative radiotherapy is the main first-intent local treatment in the form of single-fraction radiotherapy or fractionated courses. Reirradiation is a viable option for inoperable patients where spinal decompression is needed but with an increased risk of radiation-induced myelopathy (RM) and subsequent neurologic damage. This review summarizes reported data on local treatment options after initial irradiation in patients with relapsed spine metastasis and key dosimetric correlations between the risk of spinal cord injury and reirradiation technique, total dose, and time between treatments. The Linear Quadratic (LQ) model was used to convert all the published doses into biologically effective doses and normalize them to EQD2. For 3D radiotherapy, authors used cumulative doses from 55.2 Gy2/2 to 65.5 Gy2/2 EQD2 with no cases of RM mentioned. We found little evidence of RM after SBRT in the papers that met our criteria of inclusion, usually at the median reported dose to critical neural tissue around 93.5 Gy2/2. There is a lack of consistency in reporting the spinal cord dose, which leads to difficulty in pooling data.